For these reasons, we postulate that interactions between FOLR2+ TAMs co-localized with Tregs, fetal-like ECs, and ALB+ tumor epithelial cells could be impacted by anti-angiogenic therapies (Figure 2), thereby, potentially impacting immunotherapy response. Here, FOLR2 is linked to neoplasm.